Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01754402 · OUTCOME

Time to Progression

Bendamustine + Pomalidomide + Dex in R/R Multiple Myeloma · Source last updated 2024-02-20

This outcome was registered, but no numerical results were posted in the captured record.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
2 years after last dose of study drug

What was measured

Time to progression - defined as time elapsed in patients between achievement of response and disease progression

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denom Units Selected
Participants
description
Time to progression - defined as time elapsed in patients between achievement of response and disease progression
reporting Status
NOT_POSTED
time Frame
2 years after last dose of study drug
title
Time to Progression
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice